News

Apr 2025   The spring 2025 EBMT meeting held a special session on cord blood, Dr. Vanderson Rocha received the 1st Eliane Gluckman award, and the Cord Blood Association is combining their annual meeting with the AABB meeting.

Apr 2025   Individual Participant Data Meta-Analysis (IPDMA) proves that children with cerebral palsy who receive cord blood cell therapy have significant improvements in gross motor skills between 6 and 12 months later. The best responders are children with CP that are under five years old and who had some ability to walk before the therapy.

Apr 2025   There is no consensus in the medical literature as to which placenta position is most common. Plus, the placenta can "migrate". But we do know that, once you have had a C-section, your odds of having placenta previa increase.

Mar 2025   MaterCell was the first cord blood bank in Argentina and in Latin America. They have remained true to their mission to provide clients with quality services and access to regenerative medicine. Despite their refusal to cut costs and participate in price wars, MaterCell continues to be the market leader in Argentina, demonstrating that parents care about quality.

Mar 2025   The goal of Birth Equity is to provide optimal birth conditions for all mothers. In the United States, maternal mortality is three times higher among black women than among white women. Everyone who works with expectant parents should be aware of disparities in birth outcomes and strive towards holistic care for all expectant mothers.

Mar 2025   When expectant mothers work with doulas, they have better birth outcomes. Health insurance plans are finding that providing coverage for doula services pays for itself. Currently in the US, most state Medicaid plans have some form of doula coverage.

Feb 2025   The first comparison of treating cerebral palsy with cord blood (UCB-MNC) versus cord tissue (UCT-MSC) finds that response is faster with cord blood but long-term improvement is comparable with either cell type.

Feb 2025   This month South Korea launches a program which gives seriously ill patients expanded access to regenerative medicine therapies that are not yet on the market.

Jan 2025   Cartistem® from Medipost is a regenerative medicine product manufactured from cord blood that is used to treat severe knee arthritis. It has regulatory approval in South Korea since 2012, and Medipost is seeking approvals in Japan and North America. Cartistem® has been used to treat over 30,000 patients and its sales have grown by 36% per year.

Jan 2025   Effective 12 Feb. 2025, CMS will only reimburse 17 allograft products for the treatment of Diabetic Foot Ulcers, and 5 allograft products are covered for Venous Leg Ulcers. The covered products all have evidence of efficacy from randomized controlled clinical trials. Physicians seeking reimbursement for skin substitute products will have to meet strict requirements.